Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
August 11 2021 - 8:00AM
Business Wire
AditxtScore™ for COVID-19 now offered in Great
Lakes Medical Laboratory locations, allowing Michiganders and their
physicians to monitor and evaluate their COVID-19 immune
response
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a
mission to improve the health of the immune system, today announced
a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a
full-service medical reference laboratory, to offer its
AditxtScore™ for COVID-19 throughout the State of Michigan. The
AditxtScore for COVID-19 is a more comprehensive immune response
monitoring tool that tracks multiple combinations of antibody and
neutralizing antibody responses against several different antigens.
This makes it possible to assess the strength of an individual’s
immune response to the SARS-CoV-2 virus.
Under the agreement, GLML will make the AditxtScore for COVID-19
available throughout its six physical locations and mobile units in
Michigan. The initiative is part of Aditxt’s ongoing effort to
expand its immune monitoring network nationwide.
“We were drawn to Aditxt initially because it has the most
comprehensive COVID-19 immune testing solution available, allowing
us to give people clarity about their individual immune response to
COVID-19,” said Elizabeth Knisely, Chief Executive Officer of GLML.
“What I did not expect was that after receiving an AditxtScore
myself I would find that I had low immune response, despite being
vaccinated. With so much uncertainty out there right now around a
surge in breakthrough cases, we need to take the guesswork out of
the equation especially for patients who are vulnerable and
immunocompromised.”
AditxtScore for COVID-19, which was first introduced in August
2020, differentiates itself from traditional antibody tests by
delivering a detailed view of an individual’s immune response to
multiple antigens associated with COVID-19. This multiplex approach
to capturing the full spectrum of biomarkers associated with
COVID-19 delivers a highly detailed snapshot of an individual’s
immune response in a single test cycle. It also includes the
ability to measure neutralizing antibodies, the subset of
virus-specific antibodies that block infection by interfering with
cell entry of virus particles. The level of precision in
AditxtScore for COVID-19, along with its ability to measure the
neutralizing activity of IgG, IgM and IgA isotopes, can provide
clinicians with the data they need to understand the strength and
quality of each individual’s immune response to COVID-19.
“While we have seen an increase in the number of COVID-19
vaccines administered in Michigan, just under half of our
population is still not vaccinated and vaccine hesitancy remains a
significant challenge in our rural and urban areas,” said Samar
Nasry, MD, internal medicine specialist and Director of the Medical
Care1 Urgent Care in Michigan. “A lot of the hesitancy we’re seeing
is driven by misinformation, potential infection post vaccination,
and uncertainty about individual risk. The wide availability of the
AditxtScore for COVID-19 will help us address those challenges by
giving people the hard facts about their immune status.”
This information is particularly important for the millions of
immunocompromised patients who may not develop an adequate immune
response to vaccination or exposure for multiple reasons,
including: immunosuppressive disease, immunosuppressant
medications, anti-cancer medications affecting immune function, or
the presence of long-term chronic disease that has exhausted the
body’s natural immune response capacity.
“We’re thrilled to be working with GLML to bring our AditxtScore
for COVID-19 to the state of Michigan,” said Amro Albanna,
Co-founder and Chief Executive Officer of Aditxt. “Everyone’s
immune response is unique to that individual, so it’s critical to
evaluate each individual’s immune response in order to effectively
address this pandemic. Our AditxtScore for COVID-19 delivers that
personalized approach with the accessibility and efficiency needed
to scale.”
AditxtScore for COVID-19 is offered through authorized channel
partners. To find an AditxtScore Channel Partner near you, please
visit www.aditxtscore.com. AditxtScore for COVID-19 is available
for use as a CLIA-validated laboratory developed test (LDT). This
test is not for self-diagnosis and is not cleared or approved by
the FDA.
About Aditxt:
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt’s immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt’s immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s intellectual property position; the Company’s ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company’s results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
titled “Risk Factors” in the Company’s most recent Annual Report on
Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210811005085/en/
Media and Investor Relations Contact: Sunny Uberoi Chief
Communications Officer Aditxt ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024